Respiratory and Neurological Disease Management, RNA Therapeutics and Drugs for Obesity and Rare Diseases Growth Opportunities 2021 – ResearchAndMarkets.com | Financial Buzz

Respiratory and Neurological Disease Management, RNA Therapeutics and Drugs for Obesity and Rare Diseases Growth Opportunities 2021 – ResearchAndMarkets.com

The “Growth Opportunities in Respiratory and Neurological Disease Management, RNA Therapeutics, and Drugs for Obesity and Rare Diseases” report has been added to ResearchAndMarkets.com’s offering.

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) covers innovations in therapeutics development and improvement of adherence for asthma and other obstructive respiratory diseases.

It also covers emerging therapeutic modalities for neurological diseases, including orally delivered small molecules, disease modifying therapies for Alzheimer’s and other neurodegenerative diseases. Furthermore, innovations in RNA therapeutics and developments in delivery of RNAi have been discussed. A few innovations covering obesity management and personalized obesity diagnosis based on phenotype are also covered.

The Life Science, Health & Wellness TOE features disruptive technology advances in the global life sciences industry. The technologies and innovations profiled encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Innovations in Life Sciences, Health & Wellness

  • Knopp Biosciences, US
  • Clin-E-Cal Ltd, UK
  • Vida Diagnostics, US
  • Arcellx, US
  • Locanabio, US
  • Lobesity, US
  • Phenomix Sciences, US
  • Stablix, US
  • Allogeneic Cellular Therapy for Bone Disorders
  • Off-The-Shelf Product for Bone Disorders
  • Alector Inc. – Investor Dashboard
  • Oral Small-Molecule Therapeutic for Alzheimer’s Disease
  • Targeted Inhibition of Amyloid Oligomers
  • Alzheon – Investor Dashboard
  • RNA-Targeted Therapy for Neurodegenerative Diseases
  • Antisense Therapy for Treating Undruggable Diseases
  • Ionis Pharmaceuticals – Investor Dashboard
  • Tyrosine Kinase Inhibition for Multiple Disease Areas
  • Tyrosine Kinase Inhibition Targeting Mast and Glial Cells
  • Ab Science S.A. – Investor Dashboard
  • Small Molecule Therapy for Neurodegeneration
  • Oral Anti-Inflammatory Therapy for Neuroprotection
  • Medicinova Inc. Us-Investor Dashboard
  • Phio Pharmaceuticals, US
  • Fabricnano, UK

     

For more information about this report visit https://www.researchandmarkets.com/r/8zpu12

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!